Incyte (NASDAQ: INCY) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Incyte to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Volatility and Risk
Incyte has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Incyte’s peers have a beta of 1.58, indicating that their average stock price is 58% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Incyte and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte currently has a consensus price target of $145.63, indicating a potential upside of 55.27%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.88%. Given Incyte’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Incyte is more favorable than its peers.
Valuation & Earnings
This table compares Incyte and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Incyte||$1.11 billion||$104.22 million||-117.24|
|Incyte Competitors||$217.29 million||-$39.39 million||-70.52|
Incyte has higher revenue and earnings than its peers. Incyte is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
90.9% of Incyte shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 17.7% of Incyte shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Incyte and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Incyte beats its peers on 10 of the 12 factors compared.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.